Elliot Wilbur
Stock Analyst at Raymond James
(1.36)
# 3,177
Out of 4,818 analysts
54
Total ratings
33.33%
Success rate
-1.79%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $18 → $25 | $21.73 | +15.05% | 7 | Nov 8, 2024 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $68.37 | +21.40% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $6 → $4 | $0.70 | +471.27% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $11.49 | +187.21% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $24.74 | +73.81% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $2.75 | +4,263.64% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $7.81 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $14.29 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $150.91 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $9.21 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $7.44 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.58 | - | 3 | Nov 9, 2017 |
ADMA Biologics
Nov 8, 2024
Maintains: Strong Buy
Price Target: $18 → $25
Current: $21.73
Upside: +15.05%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $68.37
Upside: +21.40%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $6 → $4
Current: $0.70
Upside: +471.27%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $11.49
Upside: +187.21%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $24.74
Upside: +73.81%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $2.75
Upside: +4,263.64%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $7.81
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $14.29
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $150.91
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $9.21
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $7.44
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $23.58
Upside: -